These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 31719645)
1. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. Negami T; Araki M; Okuno Y; Terada T Sci Rep; 2019 Nov; 9(1):16586. PubMed ID: 31719645 [TBL] [Abstract][Full Text] [Related]
2. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. Zachariae U; Giordanetto F; Leach AG J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531 [TBL] [Abstract][Full Text] [Related]
3. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current. Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804 [TBL] [Abstract][Full Text] [Related]
4. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling. Du-Cuny L; Chen L; Zhang S J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220 [TBL] [Abstract][Full Text] [Related]
5. In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel. Knape K; Linder T; Wolschann P; Beyer A; Stary-Weinzinger A PLoS One; 2011; 6(12):e28778. PubMed ID: 22194911 [TBL] [Abstract][Full Text] [Related]
6. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition. Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718 [TBL] [Abstract][Full Text] [Related]
7. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Thomas D; Karle CA; Kiehn J Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254 [TBL] [Abstract][Full Text] [Related]
8. An automated docking protocol for hERG channel blockers. Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741 [TBL] [Abstract][Full Text] [Related]
9. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel. Luo F; Gu J; Chen L; Xu X Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024 [TBL] [Abstract][Full Text] [Related]
10. A novel structure-based virtual screening model for the hERG channel blockers. Du L; Li M; You Q; Xia L Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468 [TBL] [Abstract][Full Text] [Related]
11. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization. Sintra Grilo L; Carrupt PA; Abriel H; Daina A Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711 [TBL] [Abstract][Full Text] [Related]
12. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Taboureau O; Jørgensen FS Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179 [TBL] [Abstract][Full Text] [Related]
13. Stereoselective block of hERG channel by bupivacaine scrutinized at molecular level. Grilo LS; Carrupt PA; Daina A Chimia (Aarau); 2010; 64(3):165-9. PubMed ID: 21140912 [TBL] [Abstract][Full Text] [Related]
14. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules. Schmidtke P; Ciantar M; Theret I; Ducrot P J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969 [TBL] [Abstract][Full Text] [Related]
15. Revealing the structural basis of action of hERG potassium channel activators and blockers. Perry M; Sanguinetti M; Mitcheson J J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767 [TBL] [Abstract][Full Text] [Related]
16. The molecular determinants of R-roscovitine block of hERG channels. Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461 [TBL] [Abstract][Full Text] [Related]
17. Computer simulations of structure-activity relationships for HERG channel blockers. Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256 [TBL] [Abstract][Full Text] [Related]
18. Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block. Dempsey CE; Wright D; Colenso CK; Sessions RB; Hancox JC J Chem Inf Model; 2014 Feb; 54(2):601-12. PubMed ID: 24471705 [TBL] [Abstract][Full Text] [Related]
19. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. Durdagi S; Duff HJ; Noskov SY J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063 [TBL] [Abstract][Full Text] [Related]
20. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. Aronov AM J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]